Live tape
Top 8, mentions 7d7,543META2,264 mentions▲ +0.06GOOGL1,512 mentions▲ +0.02NVDA805 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT606 mentions▲ +0.06SPY572 mentions▲ +0.05QQQ564 mentions▲ +0.08TSLA554 mentions▲ +0.06

Equity · Healthcare

CLDX

Celldex Therapeutics, Inc. · NasdaqCM

$31 0.00% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 44 sessions
$45 $30 30 Jun 25 Sep

The line runs $37.22 on 30 June through $31 on 25 September, on a scale from $30 to $45. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CLDX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 44 sessions over that window: $37.22 on 30 June 2026 through $31 on 25 September 2026.

Market cap $2.4B
52-week range $23 – $43
Avg volume 175.8K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

CLDX insider trades

SEC Form 4

CLDX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 2 January 2026.

Date Insider Type Shares Value
04 Dec 2025 Jimenez Freddy A. SVP & GENERAL COUNSEL Sell 4,166 $121K
13 Nov 2025 Wright Richard M. Sell 49,298 $1.18M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Jan 2026 Martin Samuel Bates SVP AND CFO Option exercise 4,817 $50K
15 Dec 2025 PEPIN RONALD SR. VP & CBO Option exercise 19,333 $106K
13 Nov 2025 Wright Richard M. Option exercise 49,298 $693K
10 Nov 2025 Lawver Teri L SVP & Chief Commercial Officer Award 100,000

CLDX reported financials

SEC EDGAR XBRL

CLDX reported revenue of $1.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$258.8M.

Figure Reported Period
Revenue $1.5M 31 Dec 2025 fiscal year
Net income −$258.8M 31 Dec 2025 fiscal year
Diluted EPS −$3.90 31 Dec 2025 fiscal year
Total assets $782.3M 30 Jun 2026 at period end
Total equity $714.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CLDX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.94 —
31 Mar 2026 Q1 2026 $-1.18 —
31 Dec 2025 FY 2025 $-3.90 —
30 Sep 2025 Q3 2025 $-1.01 —
30 Jun 2025 Q2 2025 $-0.85 —
31 Mar 2025 Q1 2025 $-0.81 —
31 Dec 2024 FY 2024 $-2.45 —
30 Sep 2024 Q3 2024 $-0.64 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CLDX institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a CLDX position for the quarter ended 30 Jun 2026 — a combined $160.5M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Added +77.7% shares 1,182,611 $44.0M
Millennium Management Held (±25%) −6.6% shares 1,170,787 $43.6M
Fisher Asset Management Held (±25%) −2.8% shares 985,677 $36.7M
Two Sigma Investments Added +382.6% shares 661,235 $24.6M
Point72 Asset Management Trimmed −96.4% shares 117,217 $4.4M
AQR Capital Management Added +1,017.3% shares 86,893 $3.2M
Man Group New position 63,504 $2.4M
Balyasny Asset Management Trimmed −69.1% shares 26,313 $979K
D. E. Shaw & Co. Trimmed −66.3% shares 17,826 $663K
Citadel Advisors Exited

Source: SEC EDGAR 13F filings

CLDX fails-to-deliver

SEC CNS data

On 18 Aug 2026, 1,202 shares of CLDX failed to deliver (about $50K).

Settlement date Shares failed Notional % of shares out
18 Aug 2026 1,202 $50K 0.002%

Source: SEC fails-to-deliver (CNS) data